2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Exosomes from GM-CSF expressing embryonic stem cells are an effective prophylactic vaccine for cancer prevention

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          The antigenic similarity between embryos and tumors has raised the idea of using embryonic material as a preventative vaccine against neoplastic disease. Indeed, we have previously reported that a vaccine comprises allogeneic murine embryonic stem cells (ESCs) and murine fibroblasts expressing GM-CSF (to amplify immune responses) successfully blocks the outgrowth of an implantable cancer (Lewis lung carcinoma; LLC) and lung tumors generated in mice using a combination of a mutagen followed by chronic pulmonary inflammation. However, such a vaccine is obviously impractical for application to humans. The use of fibroblasts to generate GM-CSF is needlessly complicated, and intact whole ESCs carry the hazard of generating embryomas/teratomas. Here, we report the successful application of an alternative prophylactic vaccine comprises exosomes derived from murine ESCs engineered to produce GM-CSF. Vaccination of mice with these exosomes significantly slowed or blocked the outgrowth of implanted LLC while control exosomes lacking GM-CSF were ineffective. Examination of tumor-infiltrating immune cells from mice vaccinated with the GM-CSF-expressing exosomes showed robust tumor-reactive CD8 + T effector responses, Th1 cytokine responses, and higher CD8 + T effector/CD4 +CD25 +Foxp3 + T regulatory cell ratio in the tumors. We conclude that a similar vaccine derived from GM-CSF- expressing human ESCs can be employed as a preventative vaccine for humans with an increased risk of developing cancer.

          Related collections

          Author and article information

          Journal
          Oncoimmunology
          Oncoimmunology
          KONI
          koni20
          Oncoimmunology
          Taylor & Francis
          2162-4011
          2162-402X
          2019
          9 January 2019
          : 8
          : 3
          : 1561119
          Affiliations
          [a ] Immuno-Oncology Program, JG Brown Cancer Center, University of Louisville , Louisville, KY, USA
          [b ] Department of Microbiology and Immunology, University of Louisville , Louisville, KY, USA
          [c ] Department of Medicine, University of Louisville , Louisville, KY, USA
          [d ] Experimental Therapeutics Program, JG Brown Cancer Center, University of Louisville , Louisville, KY, USA
          [e ] Department of Pharmacology and Toxicology, University of Louisville , Louisville, KY, USA
          Author notes
          CONTACT Kavitha Yaddanapudi Kavitha.yaddanapudi@ 123456louisville.edu
          Chi Li Chi.li@ 123456louisville.edu University of Louisville, Clinical & Translational Research Building Suite 405, 505 S. Hancock St. Louisville, KY 40202
          [*]

          These authors contributed equally to the paper

          Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/koni.

          Article
          PMC6350682 PMC6350682 6350682 1561119
          10.1080/2162402X.2018.1561119
          6350682
          30723593
          5efcb81d-ea7c-4504-a9da-4526c989a7a5
          © 2019 Taylor & Francis Group, LLC
          History
          : 6 June 2018
          : 26 November 2018
          : 10 December 2018
          Page count
          Figures: 7, References: 50, Pages: 13
          Funding
          Funded by: Free To Breathe 10.13039/100008405
          Award ID: YRIG Award
          Funded by: National Cancer Institute 10.13039/100000054
          Award ID: AA018016-01
          Funded by: National Cancer Institute 10.13039/100000054
          Award ID: CA175003
          Funded by: National Cancer Institute 10.13039/100000054
          Award ID: CA198249
          Funded by: National Cancer Institute 10.13039/100000054
          Award ID: CA106599
          This work was supported by the Free To Breathe [YRIG Award]; NIH National Cancer Institute [AA018016-01]; NIH National Cancer Institute [CA175003]; NIH National Cancer Institute [CA198249]; NIH National Cancer Institute [CA106599].
          Categories
          Original Research

          prophylactic vaccine,exosomes,embryonic stem cells,Cancer

          Comments

          Comment on this article